指南与共识膀胱癌与上尿路尿路上皮癌泌尿系感染

美国泌尿外科协会新血尿风险分类指南的评估

Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria.
指南 / 共识 · J Urol · 2020-12-24

本研究为多国队列研究,纳入5项临床试验和2项前瞻性登记研究中的15779例接受血尿泌尿外科评估的患者,按美国泌尿外科协会(AUA)风险分层(低、中、高危)分组,主要终点为各风险层内膀胱癌发生率。结果显示低、中、高危组膀胱癌发生率分别为0.4%、1.0%和6.3%,表明该风险分层系统可将血尿患者分为膀胱癌可能性不同的临床有意义类别,支持对低、中、高危组采取递增强度的评估。

要点

  • AUA血尿风险分层将患者分为低危0.4%、中危1.0%、高危6.3%的膀胱癌发生率。
  • 高危患者占83.6%,各队列中均以高危为主。
  • 膀胱癌在男性、吸烟者、老年及肉眼血尿患者中更常见。

核心结论

  • 新的风险分层系统将血尿患者分为膀胱癌可能性不同的临床有意义类别,支持对低、中、高危组采取递增强度的评估。
  • 各风险组的膀胱癌相对发生率有助于医患沟通评估膀胱癌的风险与获益。

研究设计与样本

  • 多国队列研究,合并5项临床试验和2项前瞻性登记研究中接受血尿泌尿外科评估的当代患者。
  • 共纳入15779例患者,按性别、年龄、血尿程度和吸烟史分为AUA低、中、高危风险层。
  • 主要终点为各风险层内膀胱癌发生率。

主要发现

  • 727例(4.6%)为低危,1863例(11.8%)为中危,13189例(83.6%)为高危,高危为主在各队列中一致。
  • 共诊断857例膀胱癌,膀胱癌发生率为5.4%。
  • 膀胱癌在男性、吸烟者、老年患者和肉眼血尿患者中更常见。
  • 低、中、高危组膀胱癌发生率分别为0.4%(3例)、1.0%(18例)和6.3%(836例)。

关键数值与推荐

  • 低危组膀胱癌发生率为0.4%(3例)。
  • 中危组膀胱癌发生率为1.0%(18例)。
  • 高危组膀胱癌发生率为6.3%(836例)。

临床怎么用

  • 依据AUA风险分层对血尿患者进行递增强度的评估。
  • 利用各风险组的膀胱癌发生率进行患者咨询,权衡评估的风险与获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Microhematuria is a prevalent condition and the American Urological Association has developed a new risk-stratified approach for the evaluation of patients with microhematuria. Our objective was to provide the first evaluation of this important guideline. MATERIALS AND METHODS: This multinational cohort study combines contemporary patients from 5 clinical trials and 2 prospective registries who underwent urological evaluation for hematuria. Patients were stratified into American Urological Association risk strata (low, intermediate or high risk) based on sex, age, degree of hematuria, and smoking history. The primary end point was the incidence of bladder cancer within each risk stratum. RESULTS: A total of 15,779 patients were included in the analysis. Overall, 727 patients (4.6%) were classified as low risk, 1,863 patients (11.8%) were classified as intermediate risk, and 13,189 patients (83.6%) were classified as high risk. The predominance of high risk patients was consistent across all cohorts. A total of 857 bladder cancers were diagnosed with a bladder cancer incidence of 5.4%. Bladder cancer was more prevalent in men, smokers, older patients and patients with gross hematuria. The cancer incidence for low, intermediate and high risk groups was 0.4% (3 patients), 1.0% (18 patients) and 6.3% (836 patients), respectively. CONCLUSIONS: The new risk stratification system separates hematuria patients into clinically meaningful categories with differing likelihoods of bladder cancer that would justify evaluating the low, intermediate and high risk groups with incremental intensity. Furthermore, it provides the relative incidence of bladder cancer in each risk group which should facilitate patient counseling regarding the risks and benefits of evaluation for bladder cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Woldu SL, Ng CK, Loo RK, et al. Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria. J Urol. 2020. PMID: 33356483. doi:10.1097/JU.0000000000001550

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。